PURPOSE: Carboplatin was infused into the brainstem of cynomolgus monkeys to investigate neurotoxicity and systemic exposures following chronic local delivery. METHODS: Infusions at 0.42 microl/h were intended to deliver 0.025 (n = 2), 0.075 (n = 3), 0.25 (n = 5), and 0.75 (n = 3) mg/kg by day 30. Laboratory tests, radiographic measurements, and clinical observations were used to monitor toxicity. Blood and cerebrospinal fluid (CSF) were sampled for platinum. RESULTS: Lethargy and ataxia were observed after week 4 in the monkeys given 0.075 mg/kg, and week 2 in the monkeys given 0.25 mg/kg when the infused doses were approximately 250 and 400 microg, respectively. Rapidly progressive neurotoxicity with the 0.75 mg/kg dose required termination of the infusions at days 4-10. Hematology and chemistry values were unremarkable in all groups. Blood levels of platinum remained undetectable in 0.025 and 0.075 mg/kg dose groups. Levels in the 0.25 mg/kg group were 3.1 +/- 0.6 microg/l at 2 weeks and 5.2 +/- 0.8 microg/l at 1 month. The CSF platinum levels varied. Animals in the 0.25 mg/kg group had higher CSF levels at 2 weeks (avg. 65 microg/l, range 36-89) compared to their 1 month value (avg. 60 microg/l, range 7-170), despite the constant infusion. CONCLUSION: Carboplatin can be chronically infused into monkey brainstems. Neurotoxicity is the predominant side effect and is dose-dependent. Pharmacokinetics of local and systemic delivery are different for carboplatin. Further studies are needed to monitor toxicity at higher flow rates and to investigate drug binding to abnormal central nervous system (CNS) tissues.
PURPOSE:Carboplatin was infused into the brainstem of cynomolgus monkeys to investigate neurotoxicity and systemic exposures following chronic local delivery. METHODS: Infusions at 0.42 microl/h were intended to deliver 0.025 (n = 2), 0.075 (n = 3), 0.25 (n = 5), and 0.75 (n = 3) mg/kg by day 30. Laboratory tests, radiographic measurements, and clinical observations were used to monitor toxicity. Blood and cerebrospinal fluid (CSF) were sampled for platinum. RESULTS:Lethargy and ataxia were observed after week 4 in the monkeys given 0.075 mg/kg, and week 2 in the monkeys given 0.25 mg/kg when the infused doses were approximately 250 and 400 microg, respectively. Rapidly progressive neurotoxicity with the 0.75 mg/kg dose required termination of the infusions at days 4-10. Hematology and chemistry values were unremarkable in all groups. Blood levels of platinum remained undetectable in 0.025 and 0.075 mg/kg dose groups. Levels in the 0.25 mg/kg group were 3.1 +/- 0.6 microg/l at 2 weeks and 5.2 +/- 0.8 microg/l at 1 month. The CSF platinum levels varied. Animals in the 0.25 mg/kg group had higher CSF levels at 2 weeks (avg. 65 microg/l, range 36-89) compared to their 1 month value (avg. 60 microg/l, range 7-170), despite the constant infusion. CONCLUSION:Carboplatin can be chronically infused into monkey brainstems. Neurotoxicity is the predominant side effect and is dose-dependent. Pharmacokinetics of local and systemic delivery are different for carboplatin. Further studies are needed to monitor toxicity at higher flow rates and to investigate drug binding to abnormal central nervous system (CNS) tissues.
Authors: Sergey V Sheleg; Eugeny A Korotkevich; Edvard A Zhavrid; Galina V Muravskaya; Arnold F Smeyanovich; Yury G Shanko; Tatsiana L Yurkshtovich; Pavel B Bychkovsky; Sergey A Belyaev Journal: J Neurooncol Date: 2002-10 Impact factor: 4.130
Authors: Michael D Prados; S Clifford Schold; Howard A Fine; Kurt Jaeckle; Fred Hochberg; Laszlo Mechtler; Michael R Fetell; Surasak Phuphanich; Lynn Feun; Todd J Janus; Kathleen Ford; William Graney Journal: Neuro Oncol Date: 2003-04 Impact factor: 12.300
Authors: S Valtonen; U Timonen; P Toivanen; H Kalimo; L Kivipelto; O Heiskanen; G Unsgaard; T Kuurne Journal: Neurosurgery Date: 1997-07 Impact factor: 4.654
Authors: R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield Journal: Proc Natl Acad Sci U S A Date: 1994-03-15 Impact factor: 11.205
Authors: J N Bruce; A Falavigna; J P Johnson; J S Hall; B D Birch; J T Yoon; E X Wu; R L Fine; A T Parsa Journal: Neurosurgery Date: 2000-03 Impact factor: 4.654
Authors: R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett Journal: J Neurosurg Date: 1997-05 Impact factor: 5.115
Authors: Barry L Wenig; Jochen A Werner; Dan J Castro; Kasi S Sridhar; Harinder S Garewal; Wolfgang Kehrl; Anna Pluzanska; Olaf Arndt; Peter D Costantino; Glenn M Mills; Frank R Dunphy; Elaine K Orenberg; Richard D Leavitt Journal: Arch Otolaryngol Head Neck Surg Date: 2002-08
Authors: U W Thomale; B Tyler; V M Renard; B Dorfman; M Guarnieri; H E Haberl; G I Jallo Journal: Childs Nerv Syst Date: 2008-08-09 Impact factor: 1.475
Authors: U W Thomale; B Tyler; V Renard; B Dorfman; V P Chacko; B S Carson; E J Haberl; G I Jallo Journal: Childs Nerv Syst Date: 2008-12-10 Impact factor: 1.475
Authors: Julia Rousseau; Caroline Boudou; Rolf F Barth; Jacques Balosso; François Estève; Hélène Elleaume Journal: Clin Cancer Res Date: 2007-08-28 Impact factor: 12.531
Authors: Laure Bobyk; Magali Edouard; Pierre Deman; Julia Rousseau; Jean-François Adam; Jean-Luc Ravanat; François Estève; Jacques Balosso; Rolf F Barth; Hélène Elleaume Journal: J Exp Clin Cancer Res Date: 2012-09-20
Authors: Joshua L Wang; Rolf F Barth; Robert Cavaliere; Vinay K Puduvalli; Pierre Giglio; Russell R Lonser; J Bradley Elder Journal: PLoS One Date: 2020-12-29 Impact factor: 3.240